Drug Interaction Report

Zidesamtinib has a moderate potential interaction with Arrhythmia.

Zidesamtinib can prolong QTc and increase the risk of ventricular tachyarrhythmias (e.g., Torsade de pointes) or sudden death. Zidesamtinib has not been studied in patients with a history of QTcF greater than 450 msec on more than one assessment prior to initiation. Monitor ECGs and electrolytes before treatment and more frequently in patients with long QT syndrome, clinically significant bradyarrhythmia, or severe/uncontrolled heart failure. Withhold, reduce, or discontinue this drug based on severity.

Mobocertinib has a moderate potential interaction with Cardiomyopathy.

Mobocertinib can cause cardiac toxicity (including decreased ejection fraction, cardiomyopathy, and congestive heart failure) resulting in heart failure which can be fatal. Cardiac function (including assessment of left ventricular ejection fraction) should be monitored at baseline and during therapy. Therapy should be withheld, the dose should be reduced, or mobocertinib should be discontinued based on the severity of decreased ejection fraction or heart failure.

Mobocertinib has a major potential interaction with Electrolyte Abnormalities.

Mobocertinib can cause life-threatening QTc prolongation, including torsades de pointes, which can be fatal, and requires monitoring of QTc and electrolytes. QTc and electrolytes should be assessed at baseline and abnormalities in sodium, potassium, calcium, and magnesium should be corrected before starting mobocertinib. QTc and electrolytes should be monitored periodically during therapy. Monitoring frequency should be increased in patients with risk factors for QTc prolongation (such as patients with congenital long QT syndrome, heart disease, or electrolyte abnormalities); caution is recommended in these patients. Therapy should be withheld, the dose should be reduced, or mobocertinib should be discontinued based on the severity of QTc prolongation.

Mobocertinib has a major potential interaction with Heart Disease.

Mobocertinib can cause life-threatening QTc prolongation, including torsades de pointes, which can be fatal, and requires monitoring of QTc and electrolytes. QTc and electrolytes should be assessed at baseline and abnormalities in sodium, potassium, calcium, and magnesium should be corrected before starting mobocertinib. QTc and electrolytes should be monitored periodically during therapy. Monitoring frequency should be increased in patients with risk factors for QTc prolongation (such as patients with congenital long QT syndrome, heart disease, or electrolyte abnormalities); caution is recommended in these patients. Therapy should be withheld, the dose should be reduced, or mobocertinib should be discontinued based on the severity of QTc prolongation.

Mobocertinib has a moderate potential interaction with Heart Failure.

Mobocertinib can cause cardiac toxicity (including decreased ejection fraction, cardiomyopathy, and congestive heart failure) resulting in heart failure which can be fatal. Cardiac function (including assessment of left ventricular ejection fraction) should be monitored at baseline and during therapy. Therapy should be withheld, the dose should be reduced, or mobocertinib should be discontinued based on the severity of decreased ejection fraction or heart failure.

Zidesamtinib has a moderate potential interaction with Heart Failure.

Zidesamtinib can prolong QTc and increase the risk of ventricular tachyarrhythmias (e.g., Torsade de pointes) or sudden death. Zidesamtinib has not been studied in patients with a history of QTcF greater than 450 msec on more than one assessment prior to initiation. Monitor ECGs and electrolytes before treatment and more frequently in patients with long QT syndrome, clinically significant bradyarrhythmia, or severe/uncontrolled heart failure. Withhold, reduce, or discontinue this drug based on severity.

Mobocertinib has a major potential interaction with Hypocalcemia.

Mobocertinib can cause life-threatening QTc prolongation, including torsades de pointes, which can be fatal, and requires monitoring of QTc and electrolytes. QTc and electrolytes should be assessed at baseline and abnormalities in sodium, potassium, calcium, and magnesium should be corrected before starting mobocertinib. QTc and electrolytes should be monitored periodically during therapy. Monitoring frequency should be increased in patients with risk factors for QTc prolongation (such as patients with congenital long QT syndrome, heart disease, or electrolyte abnormalities); caution is recommended in these patients. Therapy should be withheld, the dose should be reduced, or mobocertinib should be discontinued based on the severity of QTc prolongation.

Mobocertinib has a major potential interaction with Hypokalemia.

Mobocertinib can cause life-threatening QTc prolongation, including torsades de pointes, which can be fatal, and requires monitoring of QTc and electrolytes. QTc and electrolytes should be assessed at baseline and abnormalities in sodium, potassium, calcium, and magnesium should be corrected before starting mobocertinib. QTc and electrolytes should be monitored periodically during therapy. Monitoring frequency should be increased in patients with risk factors for QTc prolongation (such as patients with congenital long QT syndrome, heart disease, or electrolyte abnormalities); caution is recommended in these patients. Therapy should be withheld, the dose should be reduced, or mobocertinib should be discontinued based on the severity of QTc prolongation.

Mobocertinib has a major potential interaction with Hyponatremia.

Mobocertinib can cause life-threatening QTc prolongation, including torsades de pointes, which can be fatal, and requires monitoring of QTc and electrolytes. QTc and electrolytes should be assessed at baseline and abnormalities in sodium, potassium, calcium, and magnesium should be corrected before starting mobocertinib. QTc and electrolytes should be monitored periodically during therapy. Monitoring frequency should be increased in patients with risk factors for QTc prolongation (such as patients with congenital long QT syndrome, heart disease, or electrolyte abnormalities); caution is recommended in these patients. Therapy should be withheld, the dose should be reduced, or mobocertinib should be discontinued based on the severity of QTc prolongation.

Zidesamtinib has a moderate potential interaction with Interstitial Lung Disease.

Zidesamtinib can cause severe or life-threatening interstitial lung disease or pneumonitis. Monitor for new or worsening pulmonary symptoms. Immediately withhold treatment if ILD/pneumonitis is suspected, and resume at same or reduced dose or permanently discontinue therapy based on severity.

Mobocertinib has a moderate potential interaction with Liver Disease.

No dosage adjustment of mobocertinib is recommended for patients with mild (total bilirubin up to the upper limit of normal [ULN] and AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN [1 to 1.5 x ULN] and any AST) or moderate (total bilirubin 1.5 to 3 x ULN and any AST) liver dysfunction. The recommended dosage of mobocertinib has not been established for patients with severe liver dysfunction (total bilirubin greater than 3 times ULN and any AST); caution is recommended in these patients.

Zidesamtinib has a moderate potential interaction with Liver Disease.

Zidesamtinib has not been studied in patients with severe liver impairment.

Zidesamtinib has a moderate potential interaction with Long QT Syndrome.

Zidesamtinib can prolong QTc and increase the risk of ventricular tachyarrhythmias (e.g., Torsade de pointes) or sudden death. Zidesamtinib has not been studied in patients with a history of QTcF greater than 450 msec on more than one assessment prior to initiation. Monitor ECGs and electrolytes before treatment and more frequently in patients with long QT syndrome, clinically significant bradyarrhythmia, or severe/uncontrolled heart failure. Withhold, reduce, or discontinue this drug based on severity.

Mobocertinib has a major potential interaction with Magnesium Imbalance.

Mobocertinib can cause life-threatening QTc prolongation, including torsades de pointes, which can be fatal, and requires monitoring of QTc and electrolytes. QTc and electrolytes should be assessed at baseline and abnormalities in sodium, potassium, calcium, and magnesium should be corrected before starting mobocertinib. QTc and electrolytes should be monitored periodically during therapy. Monitoring frequency should be increased in patients with risk factors for QTc prolongation (such as patients with congenital long QT syndrome, heart disease, or electrolyte abnormalities); caution is recommended in these patients. Therapy should be withheld, the dose should be reduced, or mobocertinib should be discontinued based on the severity of QTc prolongation.

Zidesamtinib has a moderate potential interaction with Osteoporosis.

Zidesamtinib can increase the risk of skeletal fractures, which occurred in some patients with predisposing factors including osteoporosis, bone metastasis, and age-related degenerative conditions. Promptly evaluate signs or symptoms of fracture during treatment.

Mobocertinib has a moderate potential interaction with Pulmonary Impairment.

Mobocertinib can cause interstitial lung disease (ILD)/pneumonitis, which can be fatal. Care should be exercised when using this drug in patients with preexisting pulmonary impairment. Mobocertinib should be immediately withheld in patients with suspected ILD/pneumonitis and permanently discontinued if ILD/pneumonitis is confirmed. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis.

Mobocertinib has a moderate potential interaction with Renal Dysfunction.

No dosage adjustment of mobocertinib is recommended for patients with mild to moderate renal dysfunction (estimated glomerular filtration rate [eGFR] 30 to 89 mL/min/1.73 m2 by Modification of Diet in Renal Disease equation). The recommended dosage of mobocertinib has not been established for patients with severe renal dysfunction (eGFR less than 30 mL/min/1.73 m2); caution is recommended in these patients.

Zidesamtinib has a moderate potential interaction with Renal Dysfunction.

Zidesamtinib has not been studied in patients with severe renal impairment or dialysis.